Related Experiment Video
Updated: Feb 18, 2026

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Published on: December 26, 2016
Nicotinic Acetylcholine Receptor Subtype Alpha-9 Mediates Triple-Negative Breast Cancers Based on a Spontaneous
Li-Chi Huang1, Ching-Ling Lin1, Jia-Zheng Qiu2
1Department of Endocrinology, Cathay General Hospital, Taipei, Taiwan.
Abstract:
Triple-negative breast cancer (TNBC) subtype is associated with poor prognosis and a high risk of recurrence-related death in women. Despite the aggressiveness of TNBCs, targeted TNBC therapy is not yet available in the clinic. To overcome this challenge, we generated highly metastatic TNBC cells (LM) derived from metastasized lung cells via a serial spontaneous pulmonary metastasis animal model to identify targetable molecules for attenuating the progression of TNBC metastasis. Gene analysis of primary tumor (P), first-round (1LM) and second-round (2LM) metastasized lung cells revealed that mesenchymal-related genes were significantly expressed in LM cells, especially in 2LM cells. Interestingly, α9-nAChR gene expression was also dramatically induced in LM cells, confirming our previous finding that α9-nAChR plays important roles in receptor-mediated carcinogenic signals in human breast cancer development. Using α9-nAChR as a biomarker, we transfected 2LM cells with CRISPR/Cas9 lentivirus targeting the α9-nAChR genomic region (2LM-α9-nAChR-null), showing that mesenchymal markers and the migration and invasion abilities of 2LM cells were significantly attenuated in 2LM-α9-nAChR-null cells both in vitro and in vivo. In addition, the high efficiency of editing the α9-nAChR gene using a CRISPR/Cas9 lentivirus was demonstrated by gene sequencing, genomic indel frequency and protein expression analyses. Collectively, these results confirmed those of our previous study that advanced-stage breast tumors are associated with substantially higher levels of α9-nAChR gene expression, indicating that α9-nAChR expression is essential for mediating TNBC metastasis during cancer development and may potentially act as a biomarker for targeted therapy in clinical investigations.
Insights
Targeting alpha-9 nicotinic acetylcholine receptor (α9-nAChR) can reduce triple-negative breast cancer (TNBC) metastasis. Gene editing of α9-nAChR in metastatic TNBC cells significantly decreased their invasive properties, suggesting its potential as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Triple-negative breast cancer (TNBC) presents a poor prognosis and high risk of recurrence.
- Targeted therapies for TNBC are currently lacking, necessitating the identification of novel therapeutic targets.
- Metastasis is a critical factor in TNBC progression and mortality.
Purpose of the Study:
- To identify targetable molecules for attenuating TNBC metastasis.
- To investigate the role of alpha-9 nicotinic acetylcholine receptor (α9-nAChR) in TNBC progression.
- To evaluate the therapeutic potential of targeting α9-nAChR in TNBC.
Main Methods:
- Generation of highly metastatic TNBC cells (LM) using a serial spontaneous pulmonary metastasis animal model.
- Gene expression analysis of primary and metastasized TNBC cells to identify key molecular players.
- CRISPR/Cas9 gene editing to ablate α9-nAChR in metastatic TNBC cells (2LM-α9-nAChR-null).
- In vitro and in vivo assessment of cell migration, invasion, and mesenchymal marker expression.
Main Results:
- Mesenchymal-related genes and α9-nAChR expression were significantly upregulated in metastatic TNBC cells (LM), particularly in second-round lung metastases (2LM).
- CRISPR/Cas9-mediated knockout of α9-nAChR in 2LM cells (2LM-α9-nAChR-null) significantly attenuated mesenchymal markers, migration, and invasion.
- Gene sequencing and protein expression analyses confirmed the high efficiency of α9-nAChR gene editing.
Conclusions:
- α9-nAChR expression is essential for mediating TNBC metastasis during cancer development.
- Targeting α9-nAChR holds potential for developing novel therapeutic strategies against TNBC metastasis.
- α9-nAChR may serve as a valuable biomarker for targeted therapy in clinical investigations of advanced breast cancer.

